Source: PubMed

Juliana Cepelowicz Rajter 1Michael S Sherman 2Naaz Fatteh 1Fabio Vogel 1Jamie Sacks 1Jean-Jacques Rajter 3

DOI: 10.1016/j.chest.2020.10.009

Abstract

Background: 

Ivermectin was shown to inhibit severe acute respiratory syndrome coronavirus 2 replication in vitro, which has led to off-label use, but clinical efficacy has not been described previously.

Research question: 

Does ivermectin benefit hospitalized coronavirus disease 2019 (COVID-19) patients?

Study design and methods: 

Charts of consecutive patients hospitalized at four Broward Health hospitals in Florida with confirmed COVID-19 between March 15 and May 11, 2020, treated with or without ivermectin were reviewed. Hospital ivermectin dosing guidelines were provided, but treatment decisions were at the treating physician’s discretion.

The primary outcome was all-cause in-hospital mortality. Secondary outcomes included mortality in patients with severe pulmonary involvement, extubation rates for mechanically ventilated patients, and length of stay.

Severe pulmonary involvement was defined as need for Fio2 ≥ 50%, noninvasive ventilation, or invasive ventilation at study entry. Logistic regression and propensity score matching were used to adjust for confounders.

Results: 

Two hundred eighty patients, 173 treated with ivermectin and 107 without ivermectin, were reviewed. Most patients in both groups also received hydroxychloroquine, azithromycin, or both.

Univariate analysis showed lower mortality in the ivermectin group (15.0% vs 25.2%; OR, 0.52; 95% CI, 0.29-0.96; P = .03).

Mortality also was lower among ivermectin-treated patients with severe pulmonary involvement (38.8% vs 80.7%; OR, 0.15; 95% CI, 0.05-0.47; P = .001).

No significant differences were found in extubation rates (36.1% vs 15.4%; OR, 3.11; 95% CI, 0.88-11.00; P = .07) or length of stay. After multivariate adjustment for confounders and mortality risks, the mortality difference remained significant (OR, 0.27; 95% CI, 0.09-0.80; P = .03).

One hundred ninety-six patients were included in the propensity-matched cohort.

Mortality was significantly lower in the ivermectin group (13.3% vs 24.5%; OR, 0.47; 95% CI, 0.22-0.99; P < .05), an 11.2% (95% CI, 0.38%-22.1%) absolute risk reduction, with a number needed to treat of 8.9 (95% CI, 4.5-263).

Interpretation: 

Ivermectin treatment was associated with lower mortality during treatment of COVID-19, especially in patients with severe pulmonary involvement. Randomized controlled trials are needed to confirm these findings.









Related:

 Ivermectin for Covid-19: Database of all Ivermectin COVID-19 studies – 35 trials and growing

Use of Ivermectin as a potential chemoprophylaxis for COVID-19 in Egypt : A randomised clinical trial

HCQ and Ivermectin included in multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk COVID-19

Hydroxychloroquine & Covid-19: India and France, a cruel comparison

Use of ivermectin to treat coronavirus patients approved in Slovakia

Share on facebook
Share on twitter
Share on whatsapp
On Trend

Latest Stories

Trouble in Paradise Surrounding the use of Ivermectin

In nations around the world tension mounts between physicians and caregivers seeking to prescribe what they professionally deem as safe doses of ivermectin, as an off-label treatment for COVID-19 and national health authorities, which for the most part have all taken a hostile and oppositional position against the use of the drug.

Read More »

How Ivermectin became a Target for the ‘Fraud Detectives.’

And why is ivermectin being so negatively targeted by Big Tech and Big Media? One could argue conflict of interest plays a major role, given how intertwined they are with Big Pharma and the far-reaching grasp of the BMGF. A cheap and effective early treatment for Covid-19, like ivermectin, can be seen as a significant threat to the financial interests of those involved with Covid vaccines and expensive anti-viral drugs.

Read More »

Canada: Alberta Failing on COVID-19 Vaccines and Treatment

Numerous studies and clinical observation of thousands of patients has indicated that Ivermectin is highly effective in this regard. Even low dose studies that were designed to reach the conclusion that ivermectin was not effective found a signal that indicated that Ivermectin effectively interacted with the COVID virus molecule to prevent or lessen replication of the virus.”

Read More »